Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Formula | C26H23F2N3O3 |
|||
Molecular Weight | 463.48 | CAS No. | 209984-56-5 | |
Solubility (25°C)* | In vitro | DMSO | 93 mg/mL (200.65 mM) | |
Water | Insoluble | |||
Ethanol | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
Description | DBZ (Dibenzazepine) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM in cell-free assays for APPL and Notch cleavage, respectively. | ||||
---|---|---|---|---|---|
Targets |
|
||||
In vitro | YO-01027 interacts directly with theγ-secretase complex and targets the N-terminal Presenilin fragment. Increasing concentrations of YO-01027 administered to APPL- or Notch-expressing cells leads to the progressive accumulation of APPL CTF fragments and a decrease in NICD production in a strictly dose-dependent manner. [1] 10 μM of YO-01027 reduces breast cancer stem cells (BCSC) number and activity. [2] A recent research indicates YO-01027 impairs mucin protein MUC16 biosynthesis in a concentration-dependent manner in undifferentiated cells at both preconfluent and confluent stages through Notch inhibition, but not in postmitotic stratified cells. [3] | ||||
In vivo | YO-01027, which is delivered 1 mg/mL by i.p. injection on the day of cell injection and every subsequent 3 days, YO-01027 significantly, decreases MCF7 but not MDA-MB-231 tumors and increases latency compared with control mice (18-28 days). YO-01027-treated MCF7 tumors that did form had significantly reduced tumor volumes. [2] Treatment of YO-01027 into C57BL/6 mice inhibits epithelial cell proliferation and induces goblet cell differentiation in intestinal adenomas in a dose-dependent manner. [4] |
Kinase Assay: |
|
---|---|
Cell Assay: |
|
Animal Study: |
|
Data from [Data independently produced by Journal of Pharmaceutical Investigation, 2014, 10.1007/s40005-014-0151-2]
Data from [Data independently produced by , , Cancer Res, 2016, 76(6):1641-52]
Data from [Data independently produced by , , Stem Cells, 2017, 35(4):1028-1039]
Data from [Data independently produced by , , Am J Pathol, 2016, 186(11):2945-2956]
A noncoding variant confers pancreatic differentiation defect and contributes to diabetes susceptibility by recruiting RXRA [ Nat Commun, 2024, 15(1):9771] | PubMed: 39532884 |
Notch1 blockade by a novel, selective anti-Notch1 neutralizing antibody improves immunotherapy efficacy in melanoma by promoting an inflamed TME [ J Exp Clin Cancer Res, 2024, 43(1):295] | PubMed: 39491031 |
GPA33 expression in colorectal cancer can be induced by WNT inhibition and targeted by cellular therapy [ Oncogene, 2024, ] | PubMed: 39472498 |
Patient-Induced Pluripotent Stem Cell-Derived Hepatostellate Organoids Establish a Basis for Liver Pathologies in Telomeropathies [ Cell Mol Gastroenterol Hepatol, 2023, 16(3):451-472] | PubMed: 37302654 |
HDAC6 and ERK/ADAM17 Regulate VEGF-Induced NOTCH Signaling in Lung Endothelial Cells [ Cells, 2023, 12(18)2231] | PubMed: 37759454 |
HDAC6 and ERK/ADAM17 Regulate VEGF-Induced NOTCH Signaling in Lung Endothelial Cells [ Cells, 2023, 12(18)2231] | PubMed: 37759454 |
Incongruence between transcriptional and vascular pathophysiological cell states [ Nat Cardiovasc Res, 2023, 2:2023530-549] | PubMed: 37745941 |
Incongruence between transcriptional and vascular pathophysiological cell states [ Nat Cardiovasc Res, 2023, 2:2023530-549] | PubMed: 37745941 |
Inhibition of LSD1 with bomedemstat sensitizes small cell lung cancer to immune checkpoint blockade and T cell killing [ Clin Cancer Res, 2022, CCR-22-1128] | PubMed: 35920742 |
Notch signaling functions in noncanonical juxtacrine manner in platelets to amplify thrombogenicity [ Elife, 2022, 11e79590] | PubMed: 36190110 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.